Ask AI
ProCE Banner Series

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Learning Objectives

  • Review FL disease state and NCCN Guidelines
  • Examine the study design and efficacy of MONJUVI + R2, a CD19- and CD20-targeted immunotherapy combination
  • Cover safety and dosing of MONJUVI + R2

All Events

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Upcoming Events

September

17

2025

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Additional Info

Acknowledgement

Sponsored By

Incyte